Avid Bioservices posted adjusted earnings of $0.04 per share for the quarter ending July 2022, exceeding the Zacks Consensus Estimate of $0.03 per share. Earnings were $0.10 per share in the year-ago quarter.
Revenues of $36.69 million for the quarter also topped the Zacks Consensus Estimate by 7.92%. The figure is also higher than year-ago period’s $30.75 million.
The current consensus EPS expectation is $0.02 on $31 million in revenues for the coming quarter, and $0.07 on $140 million in revenues for the current fiscal year. (as reported by Zacks Equity Research).
Engages in the developing and manufacturing of monoclonal antibody therapeutics
Industry Biotechnology